Blue Trust Inc. Has $2.91 Million Position in Pfizer Inc. (NYSE:PFE)

Blue Trust Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 8.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 114,803 shares of the biopharmaceutical company’s stock after selling 10,220 shares during the quarter. Blue Trust Inc.’s holdings in Pfizer were worth $2,909,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of PFE. Tallon Kerry Patrick purchased a new position in shares of Pfizer in the fourth quarter valued at $509,000. Brighton Jones LLC boosted its holdings in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Pfizer by 12.5% in the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares in the last quarter. Sierra Ocean LLC purchased a new position in Pfizer in the 4th quarter worth about $34,000. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Pfizer by 23.1% during the 4th quarter. Venturi Wealth Management LLC now owns 6,181 shares of the biopharmaceutical company’s stock valued at $164,000 after buying an additional 1,159 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on PFE shares. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 target price (down previously from $32.00) on shares of Pfizer in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective for the company. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim restated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. Finally, Citigroup reissued a “neutral” rating on shares of Pfizer in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $29.17.

Pfizer Trading Down 0.5%

Shares of Pfizer stock opened at $23.88 on Thursday. The company has a 50 day simple moving average of $23.17 and a two-hundred day simple moving average of $24.92. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. The firm has a market cap of $135.74 billion, a PE ratio of 17.30, a PEG ratio of 0.87 and a beta of 0.57.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm had revenue of $13.72 billion for the quarter, compared to analyst estimates of $14.43 billion. During the same period last year, the company earned $0.82 EPS. The business’s quarterly revenue was down 7.8% compared to the same quarter last year. Analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 7.20%. Pfizer’s dividend payout ratio (DPR) is 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.